STX1B

STX1B encodes syntaxin-1B, a core presynaptic SNARE protein required for Ca2+-triggered neurotransmitter release at the synapse (PMID:25362483, PMID:32572454). Its function in SNARE-mediated synaptic vesicle fusion is organized by two regulators: Munc18-1 recruits STX1B in an auto-inhibited conformation, and Munc13 catalyzes SNARE helix pairing, so that disruption of the STX1B–Munc18-1 interface produces distinct neurophysiological consequences (PMID:32572454). Disease-causing mutations partition mechanistically by domain: the G226R encephalopathy mutation reduces Munc18-1 binding, lowers STX1B and Munc18-1 expression, shrinks the readily releasable vesicle pool, and reduces evoked release, whereas the SNARE-region V216E mutation only mildly perturbs Munc18-1/Munc13 binding but enhances fusogenicity and increases release probability, and a Habc-domain InDel yields an unfolded protein that cannot sustain neurotransmission (PMID:32572454). Genotype-phenotype analysis links SNARE-motif missense variants to more severe epileptic encephalopathy and truncating loss-of-function alleles to milder epilepsy, establishing STX1B as a cause of inherited epilepsy syndromes (PMID:25362483, PMID:30737342). STX1B also directly binds PRRT2, an interaction lost with a PRRT2 truncation lacking its helix-loop-helix domain (PMID:30009426).

1. 2014 High

   Whether STX1B causally controls neurotransmitter release in vivo and underlies an epilepsy phenotype was unknown; this established its essential role in the presynaptic release machinery.

   Evidence Antisense morpholino knockdown in zebrafish with wild-type vs. mutant human STX1B rescue, scored by behavior and local field potentials

   PMID:25362483

   Open questions at the time

   • Does not resolve the molecular interactions or specific fusion step STX1B controls
   • Zebrafish knockdown does not map domain-specific functions
2. 2018 Medium

   It was unknown whether STX1B physically links to other paroxysmal-disorder proteins; this showed STX1B directly binds PRRT2 and that a disease truncation abolishes the interaction.

   Evidence Co-immunoprecipitation of PRRT2 and STX1B from transfected cells, immunofluorescence localization, Western blot of the truncation mutant

   PMID:30009426

   Open questions at the time

   • Single Co-IP in a transfected, non-neuronal system without reciprocal validation
   • Functional consequence of lost PRRT2–STX1B binding on release not measured
3. 2019 Medium

   The relationship between mutation type/location and disease severity was unclear; this established that SNARE-motif missense variants drive severe encephalopathy while truncating alleles cause milder epilepsy.

   Evidence Genotype-phenotype correlation across 49 patients in 23 families with next-generation sequencing and in silico pathogenicity prediction

   PMID:30737342

   Open questions at the time

   • Relies on clinical correlation and in silico prediction rather than direct functional assays
   • Does not define the molecular mechanism distinguishing SNARE-domain gain-of-dysfunction from haploinsufficiency
4. 2020 High

   How specific STX1B mutations alter the molecular machinery was unresolved; this assigned distinct mechanisms—loss of Munc18-1 binding and reduced release, enhanced fusogenicity, or protein unfolding—to individual mutations.

   Evidence Co-IP of STX1B mutants with Munc18-1 and Munc13, patch-clamp electrophysiology in STX1-null mouse hippocampal neurons, and Western blot of expression

   PMID:32572454

   Open questions at the time

   • No structural model of the mutant SNARE/Munc18-1 interfaces
   • Mechanism by which V216E enhances fusogenicity at the molecular level not fully defined

• How the PRRT2–STX1B interaction and the Munc18-1/Munc13-regulated SNARE cycle are integrated to set release probability across neuron types remains open.
• Functional role of PRRT2 binding in STX1B-dependent release untested in neurons
• No reconstituted or structural account unifying the domain-specific mutation effects